Main Article Content
OBJECTIVE: To study the outcomes of intravenous recombinant tissue plasminogen activator (rt-PA) therapy in acute ischemic stroke patients at Bangkok Hospital Medical Center (BMC).
MATERIALS AND METHODS: A retrospective review was performed on acute ischemic stroke patients who arrived at the hospital within three hours of symptom onset and entered the stroke pathway, from 2008 to 2012. The success of the stroke fast track was determined using the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modiÀ ed Rankin Scale (mRS) scores.
RESULTS: All 1,548 patients were enrolled in the stroke pathway at BMC from 2008 to 2012. There were 182 acute ischemic stroke patients who arrived at the hospital within 3 hours from the onset of symptoms, and 25 of them were eligible for intravenous rt-PA therapy. The patients who received rt-PA therapy demonstrated a signiÀ cant reduction in NIHSS and mRS scores, as well as a signiÀ cant increase in BI scores on the discharge day (p < 0.01).
CONCLUSION: Our data suggests favorable clinical outcomes in acute ischemic stroke patients who received rt-PA therapy, as well as the success of the stroke pathway administration system at BMC.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-83.
3. European Stroke Initiative Executive Committee. European Stroke Initiative Recommendations for Stroke Management -update 2003. Cerebrovasc Dis 2003;16:311-37.
4. The nursing society of Neurology in Thailand, Neurological Institute. Nursing Practice Guidelines of Stroke Patient for General Nurse. Bangkok: Department of Medical Services, Ministry of Public Health, 2007.
5. Pérez de la Ossa N, Millán M, Arenillas JF, et al. Influence of direct admission to Comprehensive Stroke Centers on the outcome of acute stroke patients treated with intravenous thrombolysis. J Neurol 2009;256:1270-6.
6. Joint Commission International. https://www.jointcommission international.org/CCPC-Certification.
7. Fuentes B, Gállego J, Gil-Nuñez A, et al. Guidelines for the preventive treatment of ischemic stroke and TIA (I). Update on risk factors and lifestyle. Neurologia 2012;27: 560-74.
8. Nilanont Y, Nidhinandana S, Suwanwela NC, et al. Quality of Acute Ischemic Stroke Care in Thailand: A Prospective Multicenter Countrywide Cohort Study. J Stroke Cerebrovasc Dis 2013:1-7.
9. Rajamani K, Millis S, Watson S, et al. Thrombolysis for acute ischemic stroke in Joint Commission-certified and -noncertified hospitals in Michigan. J Stroke Cerebrovasc Dis 2013;22:49-54.
10. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333: 1581-7.
11. Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006;37:1332-3.
12. Saver CL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007;38:2279-83.